Entera Bio's N-Tab Platform and Pipeline - Entera Bio's proprietary N-Tab platform transforms peptides into orally bioavailable tablets, potentially unlocking patient acceptance and driving superior health outcomes[7, 19] - The company's lead asset, EB613, is a differentiated Phase 3 asset poised for blockbuster sales as a first-in-class oral PTH(1-34) anabolic tablet treatment for osteoporosis, a condition affecting over 200 million people worldwide[7, 27] - Entera has a rich pipeline with multiple blockbuster opportunities in high-impact therapeutic areas, including EB612 for hypoparathyroidism, OXM for obesity/metabolic disorders, and GLP-2 for GI inflammatory disorders and short bowel syndrome[7, 8] - The company's cash runway extends into H2 2026, with multiple catalysts expected in the next 12 months[8] EB613 for Osteoporosis - EB613 is positioned as the first oral anabolic treatment to support earlier intervention in osteoporosis, addressing a substantial treatment gap[7, 28] - A Phase 2 study of EB613 in post-menopausal women with low bone mass or osteoporosis demonstrated a faster onset of action and higher increases in BMD at the cortical bone (femoral neck and hip region)[23] - EB613's Phase 2 results showed a distinct dual mechanism of increased bone formation (P1NP) and reduced bone resorption (CTX)[44] - Phase 2 data indicated that EB613 increased BMD at all major skeletal sites, with placebo-adjusted BMD change of EB613 2.5mg from Baseline to Month 6 as Compared with Published Forteo® Data[56, 57] GLP-1/Glucagon and GLP-2 Programs - Entera is developing an oral GLP-1/Glucagon (OXM) dual agonist tablet for metabolic disorders and obesity in partnership with OPKO, with an IND filing expected late 2025/early 2026[8, 104, 116] - Pre-clinical data supports the development of once-daily oral GLP-2 analog tablets for short bowel syndrome (SBS), a rare disease affecting approximately 30,000 patients across the US and EU[8, 106, 108]

Core Insights - DuPont de Nemours, Inc. (DD) has launched AmberChrom TQ1 chromatography resin aimed at purifying oligonucleotides and peptides for biopharma applications, enhancing its product portfolio and establishing a new benchmark in the industry [1][2][3] Group 1: Product Launch and Features - The AmberChrom TQ1 chromatography resin is an agarose-based product that offers higher loading capacity, increased throughput, and lower pressure requirements compared to competing products, making it suitable for high-resolution separations and large-scale purifications [2] - The resin is designed to work in conjunction with existing AmberChrom XT and CG chromatography resins, facilitating the purification of various oligonucleotide feeds and aiding in the crude purification of peptide feeds [3] Group 2: Performance Validation - DuPont has published internal application studies using real-world drug feeds to validate the performance characteristics of the AmberChrom TQ1 resin, supporting its integration into processes from drug discovery to commercialization [3] Group 3: Financial Outlook - For the second quarter, DuPont projects net sales of approximately $3.2 billion, operating EBITDA of around $815 million, and adjusted earnings per share of about $1.05, reflecting a seasonal increase in sales [6] - The company has maintained its full-year 2025 guidance, indicating confidence in its financial performance moving forward [6] Group 4: Stock Performance - DuPont's stock has experienced a decline of 14.5% over the past year, which is less severe compared to the industry's overall decline of 26.6% [5]

Protagonist Therapeutics (PTGX) Update / Briefing February 06, 2025 10:30 AM ET Speaker0 Good morning, everybody. Thanks for joining us. I'm Corey Davis with LifeSci Advisors. Welcome to our PV Day with Protagonist Therapeutics to review the current PV market and set the stage for the upcoming Phase III data that are expected in March. We have got two KOLs and a number of company executives to walk through what I hope will be a scintillating presentation. We've got about 40 people in the room and over 100 p ...